New Migraine Drugs Target CGRP
There are currently 3 drugs being studied that target CGRP. One drug showed a reduction of 66% compared to a 52% placebo group reduction in migraine days. Sixteen percent were headache-free while none of the placebo patients were. The second drug had a 63% reduction compared to 42% in placebo group. No safety issues were noted.
Our center is a site in a research study with a third drug, which is a monoclonal antibody directed against CGRP, a pain transmitter critical in the migraine process.
Dr. Florin is committed to treating all patients compassionately with state-of-the-art techniques while maintaining their dignity and independence. He views each patient encounter as a collaboration. Dr Florin has over 35 years of experience. He is Adjunct Clinical Professor at Keck School of Medicine (USC) and is the founder and medical director of the Fullerton Neurology and Headache Center. He has been recognized by the Orange County Medical Association as a Physician of Excellence in Neurology. US News and World Report ranks him in the top 10% of neurologists nationwide.
Leave a Reply